Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCCLG-ALL-2016 regimen study in children with acute lymphoblastic leukemia
ChiCTR2000030357Phase 4Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methotrexate and pegaspargase in acute lymphoblastic leukemia (ALL) (5 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Remission rate, 40-day remission with incomplete hematologic recovery and 3 more. Started Mar 2020; status: recruiting.
02
Drugs
methotrexatepegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2000030357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030357.